Key regions: Japan, India, Italy, Brazil, South Korea
The Anti-Hypertensive Drugs market in EU-27 has been experiencing steady growth in recent years. Hypertension, or high blood pressure, is a common health condition that affects a significant portion of the population in Europe. As a result, the demand for anti-hypertensive drugs has been on the rise.
Customer preferences: Patients in the EU-27 region have shown a preference for combination therapies that include multiple classes of anti-hypertensive drugs. This is due to the fact that hypertension is often caused by multiple factors, and a combination of drugs can target these different causes more effectively. Additionally, patients are increasingly seeking out drugs with fewer side effects and a more convenient dosing schedule.
Trends in the market: The European anti-hypertensive drugs market has been dominated by a few key players, with a high level of consolidation in the industry. However, there has been a recent trend towards the development of generic drugs, which has increased competition and driven down prices. This has been particularly evident in countries where healthcare costs are a major concern, such as Greece and Portugal.
Local special circumstances: There are several factors that have influenced the development of the anti-hypertensive drugs market in specific countries within the EU-27 region. For example, in Germany, the use of fixed-dose combination therapies has been increasing, while in France, there has been a shift towards the use of calcium channel blockers. In Italy, there has been a focus on reducing healthcare costs, which has led to an increase in the use of generic drugs.
Underlying macroeconomic factors: The aging population in Europe has been a major driver of growth in the anti-hypertensive drugs market, as hypertension is more common in older individuals. Additionally, the high prevalence of risk factors such as obesity and diabetes has contributed to the increasing incidence of hypertension. The economic downturn in Europe has also had an impact on the market, as patients are more likely to seek out lower-cost generic drugs. Finally, the increasing focus on preventative healthcare and disease management has led to greater awareness of hypertension and the importance of managing it effectively.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
